Takeda’s Qdenga gets India approval, targets H1 2027 private-market launch
Takeda’s Qdenga has become the first dengue vaccine approved in India. The two-dose vaccine is indicated for people aged 4–60 and is expected to reach private healthcare channels in H1 2027, supported by manufacturing partnerships with Biological E and Indian Immunologicals.
What happened
Takeda Pharmaceutical India · Takeda’s Qdenga became the first dengue vaccine approved in India and is targeted for private-healthcare availability in H1 2027.
Key facts
- Qdenga expected to be available in India in H1 2027
- Global manufacturing target: 100 million doses annually by 2030
- Biological E partnership could support production of up to 50 million doses annually
- India recorded 232,425 dengue cases and 233 deaths in 2024
- Vaccine indicated for people aged 4 to 60 years
- Two 0.5 ml doses administered three months apart
- 80.2% efficacy against confirmed cases one year after dose two
- 90.4% efficacy against dengue-related hospitalizations after 18 months
- Approved in 43 countries
Why this matters
Healthcare platforms, pharmacy chains and diagnostics providers should explore partnerships with Takeda and its manufacturing allies to bundle vaccination, screening and travel-health services before the category matures.
What to watch
- Final private-market price, provider margin, and availability of patient-financing or installment options.
- WHO guidance, Indian public-health recommendations, and any National Immunization Programme evaluation or procurement signal.
- Evidence and regulatory communication on efficacy by prior dengue exposure, safety monitoring, and real-world Indian outcomes.
- Manufacturing-transfer milestones, local fill-finish capacity, cold-chain readiness, and launch inventory commitments.
- Insurer coverage decisions, employer vaccination-program adoption, and hospital-chain formulary listings.
- Dengue incidence during 2026-2027 monsoon seasons, especially in major private-healthcare catchments.
- Competitive vaccine approvals, domestic manufacturer partnerships, or lower-priced entrants.
- Private hospital chains should secure early allocation, train pediatric and infectious-disease clinicians, and build two-dose recall workflows before the 2027 launch.
- Pharmacy chains and e-pharmacies should assess vaccination-center partnerships, cold-chain capacity, digital prescription pathways, and monsoon-season demand campaigns.
- Health insurers and employers should test reimbursement or wellness-bundle pilots for high-risk geographies, initially targeting corporate families and covered children.
- Diagnostics players should pair dengue testing, physician referral, and prevention education while avoiding messaging that implies vaccination replaces diagnosis or vector control.
- Consumer-health retailers should prepare seasonal dengue-prevention bundles spanning repellents, mosquito-control products, testing access, and vaccine appointment referrals.